<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423084</url>
  </required_header>
  <id_info>
    <org_study_id>V72_41</org_study_id>
    <nct_id>NCT01423084</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years</brief_title>
  <official_title>A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the equivalence of rMenB+OMV NZ lot 1
      to rMenB+OMV NZ lot 2 when administered to adolescents, as measured by human serum
      bactericidal activity (hSBA) geometric mean titers (GMTs) against 3 N. meningitidis serogroup
      B reference strains (H44/76, 5/99, and NZ98/254) and as measured by ELISA geometric mean
      concentrations (GMCs) against vaccine antigen 287-953, approximately 30 days after a primary
      vaccination course of two doses administered one month apart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Novartis will consider this study a success if, at one month following the second
      vaccination, the two-sided 95% CI of the ratio of the hSBA GMTs for each of 3 serogroup B
      reference strains (H44/76, 5/99, and NZ98/254) and the two-sided 95% CI of the ratio of the
      ELISA GMCs against vaccine antigen 287-953 are contained within the interval (0.5, 2.0).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.</measure>
    <time_frame>One month after the second vaccination (day 61)</time_frame>
    <description>Consistency of the immune response of the two lots of rMenB+OMV NZ will be assessed at one month after the second vaccination based on the ratio of the vaccine lot hSBA GMTs for each of three serogroup B reference strains (H44/76, 5/99, and NZ98/254) and based on the ratio of Enzyme-linked Immunosorbent Assay (ELISA) GMCs for vaccine antigen 287-953. The equivalence interval will be (0.5, 2.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ELISA Geometric Mean Concentration (GMCs) Against Vaccine Antigen 287-953</measure>
    <time_frame>One month after the second vaccination (day 61)</time_frame>
    <description>The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects in Each Lot With hSBA ≥ 1:5</measure>
    <time_frame>One month after the second vaccination (day 61)</time_frame>
    <description>The percentage of subjects in each lot with hSBA ≥ 1:5 at one month after the second vaccination for each of the three reference strains (H44/76, 5/99, and NZ98/254) for each vaccine group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMR) of GMTs Against Each of N. Meningitidis Serogroup B Reference Strains.</measure>
    <time_frame>One month after the second vaccination (day 61)</time_frame>
    <description>The immune response of two different lots of rMenB+OMV NZ against each of N. meningitidis serogroup B test strains is evaluated in terms of GMR between GMTs (1month after the second vaccination vs baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMR) of ELISA Geometric Mean Concentration (GMCs) Against Antigen 287-953</measure>
    <time_frame>One month after the second vaccination (day 61)</time_frame>
    <description>The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 61 vs baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.</measure>
    <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
    <description>The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of hSBA GMT against 3 N. Meningitidis serogroup B reference strains at two weeks after last vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMRs of GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.</measure>
    <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
    <description>The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of GMRs of GMT against 3 N.
meningitidis serogroup B reference strains at two weeks after last vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥1:5 Against Each of N. Meningitidis Serogroup B Reference Strains at Day 45.</measure>
    <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
    <description>The immune response of two different lots of rMenB+OMV NZ against each of N. Meningitidis serogroup B reference strains is evaluated in terms of percentages of subjects with hSBA ≥1:5 two weeks after the last vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA GMCs Against Vaccine Antigen 287-953 at Day 45.</measure>
    <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
    <description>The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMR of ELISA GMCs Against Antigen 287-953 at Day 45.</measure>
    <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
    <description>The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 45 vs baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)</measure>
    <time_frame>From day 1 to day 7 after any vaccination</time_frame>
    <description>Number of subjects reporting solicited local and systemic Adverse Events and other indicators of reactogenicity after any vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited AEs</measure>
    <time_frame>From day 1 to day 7 after any vaccination.</time_frame>
    <description>Number of subjects reporting any Unsolicited AEs after any vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting SAEs and AE Leading to Withdrawal</measure>
    <time_frame>Throughout the study period.</time_frame>
    <description>Number of subjects reporting any Serious AEs (SAEs), medically attended AEs and AEs that result in a subject's withdrawal from the study after any vaccination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Meningococcal Disease</condition>
  <condition>Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>MenB Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MenB vaccine Lot 1: 2 doses administered 1 month apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenB Lot 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MenB vaccine Lot 2: 2 doses administered 1 month apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serogroup B meningococcal vaccine</intervention_name>
    <description>All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.
A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination</description>
    <arm_group_label>MenB Lot 1</arm_group_label>
    <arm_group_label>MenB Lot 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects (11-17 years of age inclusive) who have given their written
             assent and whose parents or legal guardians have given written informed consent at the
             time of enrollment

          -  who are available for all the visits scheduled in the study (i.e., not planning to
             leave the area before the end of the study period)

          -  in good health as determined by the outcome of medical history, physical examination
             and clinical judgment of the investigator.

        Exclusion Criteria:

          -  History of any serogroup B meningococcal vaccination

          -  Current or previous, confirmed or suspected disease caused by N. meningitidis

          -  Exposure to an individual with any laboratory confirmed N. meningitidis infection
             within 60 days of enrollment

          -  Significant acute or chronic infection within the previous 7 days or fever (defined as
             axillary temperature ≥ 38.0 °C) within the previous day

          -  Antibiotic use within 3 days (72 hours) prior to enrollment

          -  Pregnancy or nursing (breastfeeding) mothers

          -  Females of childbearing age who have not used or do not plan to use acceptable birth
             control measures, for the 2 months duration of the study. If sexually active the
             subject must have been using one of the accepted birth control methods for at least 30
             days prior to study entry

          -  Any serious chronic or progressive disease, Known or suspected impairment/alteration
             of the immune system

          -  Receipt of blood, blood products and/or plasma derivatives, or a parenteral
             immunoglobulin preparation within the previous 90 days

          -  History of severe allergic reactions after previous vaccinations or hypersensitivity
             to any vaccine component
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AusTrials Pty Ltd-Suites 6, 10 &amp; 11, Peninsula Specialist Centre</name>
      <address>
        <city>Kippa-Ring</city>
        <state>Queensland</state>
        <zip>4021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AusTrials Pty Ltd-Suite 5, Level 1, 14 Primrose Street</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital, 72 King William Road</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murdoch Children's Research Institute-Level 5, 207 Bouverie St-University of Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Telethon Institute for Child Heath Research-cnr</name>
      <address>
        <city>Hamilton Street and Roberts Road-Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TASC Research Services, 1-15243 91st Avenue</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 8P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colchester Regional Hospital Colchester Research Group, 68 Robie Street</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albion Finch Medical Centre, 1620 Albion Road, Suite 106</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicor Research Inc, 359 Riverside, Suite 200</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDS Research Inc, 221-679 Davis Dr.Newmarket</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Hartley Garfield Medicine Professional Corporation, 790 Bay Street, Suite 540</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devonshire Clinical Research INC, 423 Devonshire Ave., Suite 301</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>February 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2015</results_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal Meningitis</keyword>
  <keyword>prevention, vaccination</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Actual start date of recruiting was 30 August 2011. Subjects were recruited from 7 centres in Canada and 6 centres in Australia.</recruitment_details>
      <pre_assignment_details>All subjects were enrolled in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>4CMenB_Rosia</title>
          <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
        </group>
        <group group_id="P2">
          <title>4CMenB_Siena</title>
          <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>adolescents aged 11-17 years</population>
      <group_list>
        <group group_id="B1">
          <title>4CMenB_Rosia</title>
          <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
        </group>
        <group group_id="B2">
          <title>4CMenB_Siena</title>
          <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="170"/>
            <count group_id="B2" value="174"/>
            <count group_id="B3" value="344"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.6" spread="1.9"/>
                    <measurement group_id="B2" value="13.8" spread="1.8"/>
                    <measurement group_id="B3" value="13.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.</title>
        <description>Consistency of the immune response of the two lots of rMenB+OMV NZ will be assessed at one month after the second vaccination based on the ratio of the vaccine lot hSBA GMTs for each of three serogroup B reference strains (H44/76, 5/99, and NZ98/254) and based on the ratio of Enzyme-linked Immunosorbent Assay (ELISA) GMCs for vaccine antigen 287-953. The equivalence interval will be (0.5, 2.0).</description>
        <time_frame>One month after the second vaccination (day 61)</time_frame>
        <population>Per Protocol Set population</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.</title>
          <description>Consistency of the immune response of the two lots of rMenB+OMV NZ will be assessed at one month after the second vaccination based on the ratio of the vaccine lot hSBA GMTs for each of three serogroup B reference strains (H44/76, 5/99, and NZ98/254) and based on the ratio of Enzyme-linked Immunosorbent Assay (ELISA) GMCs for vaccine antigen 287-953. The equivalence interval will be (0.5, 2.0).</description>
          <population>Per Protocol Set population</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" lower_limit="96" upper_limit="129"/>
                    <measurement group_id="O2" value="111" lower_limit="96" upper_limit="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.27" lower_limit="7.44" upper_limit="12"/>
                    <measurement group_id="O2" value="11" lower_limit="9.22" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain (N=152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183" lower_limit="160" upper_limit="209"/>
                    <measurement group_id="O2" value="199" lower_limit="174" upper_limit="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Equivalence of 2 different lots of rMenB+OMV NZ in terms of hSBA GMTs against H44/76 strain</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two different lots of rMenB+OMV NZ are to be considered equivalent in terms of hSBA GMTs against H44/76 strain if the two sided 95% Confidence Interval (CI) between groups GMTs ratio at day 31 (ie, one month after the second vaccination) does not exceed the range 0.5 (lower limit) - 2.0 (higher limit).</non_inferiority_desc>
            <param_type>between groups ratio</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Equivalence of 2 different lots of rMenB+OMV NZ in terms of hSBA GMTs against 5/99 strain</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two different lots of rMenB+OMV NZ are to be considered equivalent in terms of hSBA GMTs against 5/99 strain if the two sided 95% Confidence Interval (CI) between groups GMTs ratio at day 31 (ie, one month after the second vaccination ) does not exceed the range 0.5 (lower limit) - 2.0 (higher limit).</non_inferiority_desc>
            <param_type>between groups ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Equivalence of 2 different lots of rMenB+OMV NZ in terms of hSBA GMTs against NZ98/254 strain</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two different lots of rMenB+OMV NZ are to be considered equivalent in terms of hSBA GMTs against NZ 98/254 strain if the two sided 95% Confidence Interval (CI) between groups GMTs ratio at day 31 (ie, one month after the second vaccination ) does not exceed the range 0.5 (lower limit) - 2.0 (higher limit).</non_inferiority_desc>
            <param_type>between groups ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects in Each Lot With hSBA ≥ 1:5</title>
        <description>The percentage of subjects in each lot with hSBA ≥ 1:5 at one month after the second vaccination for each of the three reference strains (H44/76, 5/99, and NZ98/254) for each vaccine group</description>
        <time_frame>One month after the second vaccination (day 61)</time_frame>
        <population>Per Protocol Set population</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects in Each Lot With hSBA ≥ 1:5</title>
          <description>The percentage of subjects in each lot with hSBA ≥ 1:5 at one month after the second vaccination for each of the three reference strains (H44/76, 5/99, and NZ98/254) for each vaccine group</description>
          <population>Per Protocol Set population</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain (N=151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 strain (N=151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="62" upper_limit="77"/>
                    <measurement group_id="O2" value="79" lower_limit="72" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio (GMR) of GMTs Against Each of N. Meningitidis Serogroup B Reference Strains.</title>
        <description>The immune response of two different lots of rMenB+OMV NZ against each of N. meningitidis serogroup B test strains is evaluated in terms of GMR between GMTs (1month after the second vaccination vs baseline).</description>
        <time_frame>One month after the second vaccination (day 61)</time_frame>
        <population>Per Protocol Set Population</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) of GMTs Against Each of N. Meningitidis Serogroup B Reference Strains.</title>
          <description>The immune response of two different lots of rMenB+OMV NZ against each of N. meningitidis serogroup B test strains is evaluated in terms of GMR between GMTs (1month after the second vaccination vs baseline).</description>
          <population>Per Protocol Set Population</population>
          <units>Ratio of GMTs</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain (N=151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" lower_limit="89" upper_limit="121"/>
                    <measurement group_id="O2" value="107" lower_limit="92" upper_limit="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 strain (N=151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.63" lower_limit="6.99" upper_limit="11"/>
                    <measurement group_id="O2" value="11" lower_limit="8.99" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" lower_limit="133" upper_limit="183"/>
                    <measurement group_id="O2" value="167" lower_limit="143" upper_limit="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio (GMR) of ELISA Geometric Mean Concentration (GMCs) Against Antigen 287-953</title>
        <description>The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 61 vs baseline).</description>
        <time_frame>One month after the second vaccination (day 61)</time_frame>
        <population>Per Protocol Set Population</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) of ELISA Geometric Mean Concentration (GMCs) Against Antigen 287-953</title>
          <description>The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 61 vs baseline).</description>
          <population>Per Protocol Set Population</population>
          <units>Ratio of GMTs</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" lower_limit="103" upper_limit="143"/>
                    <measurement group_id="O2" value="153" lower_limit="131" upper_limit="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.</title>
        <description>The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of hSBA GMT against 3 N. Meningitidis serogroup B reference strains at two weeks after last vaccination.</description>
        <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
        <population>Per Protocol Set, immunogenicity subset</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>MenB Lot 2</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.</title>
          <description>The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of hSBA GMT against 3 N. Meningitidis serogroup B reference strains at two weeks after last vaccination.</description>
          <population>Per Protocol Set, immunogenicity subset</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187" lower_limit="152" upper_limit="229"/>
                    <measurement group_id="O2" value="171" lower_limit="139" upper_limit="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="18"/>
                    <measurement group_id="O2" value="20" lower_limit="15" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254" lower_limit="206" upper_limit="314"/>
                    <measurement group_id="O2" value="339" lower_limit="273" upper_limit="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMRs of GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.</title>
        <description>The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of GMRs of GMT against 3 N.
meningitidis serogroup B reference strains at two weeks after last vaccination.</description>
        <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
        <population>Per Protocol Set, Immunogenicity subset</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>GMRs of GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.</title>
          <description>The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of GMRs of GMT against 3 N.
meningitidis serogroup B reference strains at two weeks after last vaccination.</description>
          <population>Per Protocol Set, Immunogenicity subset</population>
          <units>Ratio of GMTs</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" lower_limit="138" upper_limit="219"/>
                    <measurement group_id="O2" value="157" lower_limit="124" upper_limit="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9.87" upper_limit="17"/>
                    <measurement group_id="O2" value="20" lower_limit="15" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214" lower_limit="161" upper_limit="284"/>
                    <measurement group_id="O2" value="243" lower_limit="183" upper_limit="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥1:5 Against Each of N. Meningitidis Serogroup B Reference Strains at Day 45.</title>
        <description>The immune response of two different lots of rMenB+OMV NZ against each of N. Meningitidis serogroup B reference strains is evaluated in terms of percentages of subjects with hSBA ≥1:5 two weeks after the last vaccination.</description>
        <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
        <population>Per Protocol Population, immunogenicity subset</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥1:5 Against Each of N. Meningitidis Serogroup B Reference Strains at Day 45.</title>
          <description>The immune response of two different lots of rMenB+OMV NZ against each of N. Meningitidis serogroup B reference strains is evaluated in terms of percentages of subjects with hSBA ≥1:5 two weeks after the last vaccination.</description>
          <population>Per Protocol Population, immunogenicity subset</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H44/76 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NZ98/254 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="74" upper_limit="92"/>
                    <measurement group_id="O2" value="96" lower_limit="88" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/99 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ELISA GMCs Against Vaccine Antigen 287-953 at Day 45.</title>
        <description>The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.</description>
        <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
        <population>Per Protocol Set, immunogenicity subset.</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA GMCs Against Vaccine Antigen 287-953 at Day 45.</title>
          <description>The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.</description>
          <population>Per Protocol Set, immunogenicity subset.</population>
          <units>IU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3742" lower_limit="2994" upper_limit="4676"/>
                    <measurement group_id="O2" value="4798" lower_limit="3825" upper_limit="6019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ELISA Geometric Mean Concentration (GMCs) Against Vaccine Antigen 287-953</title>
        <description>The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.</description>
        <time_frame>One month after the second vaccination (day 61)</time_frame>
        <population>Per Protocol Set population</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISA Geometric Mean Concentration (GMCs) Against Vaccine Antigen 287-953</title>
          <description>The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.</description>
          <population>Per Protocol Set population</population>
          <units>IU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2729" lower_limit="2338" upper_limit="3186"/>
                    <measurement group_id="O2" value="3291" lower_limit="2829" upper_limit="3828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Equivalence of 2 different lots of rMenB+OMV NZ in terms of hSBA GMTs</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Two different lots of rMenB+OMV NZ are to be considered equivalent in terms of ELISA GMCs against vaccine antigen 287-953 if the two sided 95% Confidence Interval (CI) between groups GMTs ratio at day 31 (ie, one month after the second vaccination ) does not exceed the range 0.5 (lower limit) - 2.0 (higher limit).</non_inferiority_desc>
            <param_type>between groups ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMR of ELISA GMCs Against Antigen 287-953 at Day 45.</title>
        <description>The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 45 vs baseline).</description>
        <time_frame>Two weeks after the second vaccination (day 45)</time_frame>
        <population>Per Protocol Set, immunogenicity subset</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>GMR of ELISA GMCs Against Antigen 287-953 at Day 45.</title>
          <description>The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 45 vs baseline).</description>
          <population>Per Protocol Set, immunogenicity subset</population>
          <units>Ratio of GMTs</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166" lower_limit="130" upper_limit="213"/>
                    <measurement group_id="O2" value="217" lower_limit="169" upper_limit="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)</title>
        <description>Number of subjects reporting solicited local and systemic Adverse Events and other indicators of reactogenicity after any vaccination.</description>
        <time_frame>From day 1 to day 7 after any vaccination</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)</title>
          <description>Number of subjects reporting solicited local and systemic Adverse Events and other indicators of reactogenicity after any vaccination.</description>
          <population>Safety Set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (&gt;= 38C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of analgesics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited AEs</title>
        <description>Number of subjects reporting any Unsolicited AEs after any vaccination.</description>
        <time_frame>From day 1 to day 7 after any vaccination.</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited AEs</title>
          <description>Number of subjects reporting any Unsolicited AEs after any vaccination.</description>
          <population>Safety Set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting SAEs and AE Leading to Withdrawal</title>
        <description>Number of subjects reporting any Serious AEs (SAEs), medically attended AEs and AEs that result in a subject’s withdrawal from the study after any vaccination.</description>
        <time_frame>Throughout the study period.</time_frame>
        <population>Safety Set</population>
        <group_list>
          <group group_id="O1">
            <title>4CMenB_Rosia</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
          </group>
          <group group_id="O2">
            <title>4CMenB_Siena</title>
            <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting SAEs and AE Leading to Withdrawal</title>
          <description>Number of subjects reporting any Serious AEs (SAEs), medically attended AEs and AEs that result in a subject’s withdrawal from the study after any vaccination.</description>
          <population>Safety Set</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs were collected from day 1 through study termination, other AEs were collected from day 1 to day 7 after vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>4CMenB_Rosia</title>
          <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility.</description>
        </group>
        <group group_id="E2">
          <title>4CMenB_Siena</title>
          <description>Subjects received two doses of rMenB+OMV NZ vaccine from lot 2 manufactured at Siena facility.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="165" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="171" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="68" subjects_affected="49" subjects_at_risk="169"/>
                <counts group_id="E2" events="77" subjects_affected="56" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 14.1">Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="129" subjects_affected="75" subjects_at_risk="169"/>
                <counts group_id="E2" events="138" subjects_affected="85" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 14.1">injection site induration</sub_title>
                <counts group_id="E1" events="96" subjects_affected="65" subjects_at_risk="169"/>
                <counts group_id="E2" events="107" subjects_affected="75" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="177" subjects_affected="111" subjects_at_risk="169"/>
                <counts group_id="E2" events="175" subjects_affected="111" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="337" subjects_affected="162" subjects_at_risk="169"/>
                <counts group_id="E2" events="349" subjects_affected="170" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 14.1">injection site swelling</sub_title>
                <counts group_id="E1" events="115" subjects_affected="80" subjects_at_risk="169"/>
                <counts group_id="E2" events="107" subjects_affected="74" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="28" subjects_at_risk="169"/>
                <counts group_id="E2" events="66" subjects_affected="45" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="169" subjects_affected="99" subjects_at_risk="169"/>
                <counts group_id="E2" events="189" subjects_affected="118" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 14.1">Headache</sub_title>
                <counts group_id="E1" events="124" subjects_affected="75" subjects_at_risk="169"/>
                <counts group_id="E2" events="159" subjects_affected="89" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None reported</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

